Here we focus on two of the most promising epigenetic regulatory proteins; enhancer of zeste homology 2 (EZH2) and lysine-specific demethylase 1A (LSD1), both of which are now being tested in current and upcoming SCLC clinical trials. The gene discussed is EZH2; the disease is small cell lung carcinoma.